Akebia Therapeutics
AKBA
$1.34
Share price
0.75%
Change (1 day)
47.25%
Change (1 year)
Categories
Akebia Therapeutics (AKBA) - Cash on Hand
Cash on Hand as of December 2023 : $42.92 M
According to Akebia Therapeutics's latest financial reports the company has $42.92 M in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Akebia Therapeutics - Cash on Hand chart (from 2013 to 2023)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2023-12-31 | $42.92 M | -52.55% |
| 2022-12-31 | $90.46 M | -39.61% |
| 2021-12-31 | $0.14 B | -44.25% |
| 2020-12-31 | $0.26 B | 81.92% |
| 2019-12-31 | $0.14 B | -54.08% |
| 2018-12-31 | $0.32 B | 1.21% |
| 2017-12-31 | $0.31 B | 22.07% |
| 2016-12-31 | $0.26 B | 88.04% |
| 2015-12-31 | $0.13 B | 27.12% |
| 2014-12-31 | $0.10 B | 234.56% |
| 2013-12-31 | $32.55 M | 1883.87% |
| 2012-12-31 | $1.64 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $22.92 B | 53,311.76% | 🇺🇸 USA |
 Novartis NVS | $9.69 B | 22,483.58% | 🇨🇭 Switzerland |
 Amgen AMGN | $10.94 B | 25,395.63% | 🇺🇸 USA |
 Nektar Therapeutics
NKTR | $0.30 B | 607.32% | 🇺🇸 USA |